4-Propylamphetamine

Apr 26, 2026 - 15:23
0 0
4-Propylamphetamine

← Previous revision Revision as of 09:51, 26 April 2026
Line 21: Line 21:
}}
}}


'''4-Propylamphetamine''' ('''4-PrA)''' is a [[serotonin receptor modulator]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] families.{{cite journal | vauthors = Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S | title = Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 4 | pages = 734–740 | date = February 1992 | pmid = 1542100 | doi = 10.1021/jm00082a014 }}{{cite book | last1=Trachsel | first1=D. | last2=Lehmann | first2=D. | last3=Enzensperger | first3=C. | title=Phenethylamine: von der Struktur zur Funktion | trans-title = Phenethylamines: From Structure to Function | edition = 1 | publisher=Nachtschatten-Verlag | location = Solothurn | series=Nachtschatten-Science | year=2013 | isbn=978-3-03788-700-4 | oclc = 858805226 | url=https://books.google.com/books?id=-Us1kgEACAAJ | language=de | archive-url=https://archive.org/details/phenethylamine-von-der-struktur-zur-funktion-trachsel-lehmann-enzensperger-2013 | archive-date=21 August 2025}} It has shown weak [[affinity (pharmacology)|affinity]] for the [[serotonin]] [[5-HT2A receptor|5-HT2A]] and [[5-HT2C receptor|5-HT2C receptor]]s (Ki = 1,250{{nbsp}}nM and 2,345{{nbsp}}nM, respectively). The drug was described by [[Richard Glennon]] and colleagues in 1992.
'''4-Propylamphetamine''' ('''4-PrA'''or''' 4-PPA''') is a [[serotonin receptor modulator]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] families.{{cite journal | vauthors = Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S | title = Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity | journal = Journal of Medicinal Chemistry | volume = 35 | issue = 4 | pages = 734–740 | date = February 1992 | pmid = 1542100 | doi = 10.1021/jm00082a014 }}{{cite book | last1=Trachsel | first1=D. | last2=Lehmann | first2=D. | last3=Enzensperger | first3=C. | title=Phenethylamine: von der Struktur zur Funktion | trans-title = Phenethylamines: From Structure to Function | edition = 1 | publisher=Nachtschatten-Verlag | location = Solothurn | series=Nachtschatten-Science | year=2013 | isbn=978-3-03788-700-4 | oclc = 858805226 | url=https://books.google.com/books?id=-Us1kgEACAAJ | language=de | archive-url=https://archive.org/details/phenethylamine-von-der-struktur-zur-funktion-trachsel-lehmann-enzensperger-2013 | archive-date=21 August 2025}} It has shown weak [[affinity (pharmacology)|affinity]] for the [[serotonin]] [[5-HT2A receptor|5-HT2A]] and [[5-HT2C receptor|5-HT2C receptor]]s (Ki = 1,250{{nbsp}}nM and 2,345{{nbsp}}nM, respectively). The drug was described by [[Richard Glennon]] and colleagues in 1992.


==See also==
==See also==
Read More